Found: 16
Select item for more details and to access through your institution.
Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial.
- Published in:
- International Journal of Neuropsychopharmacology, 2022, v. 25, n. 3, p. 252, doi. 10.1093/ijnp/pyab074
- By:
- Publication type:
- Article
A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults.
- Published in:
- Therapeutic Advances in Psychopharmacology, 2023, v. 13, p. 1, doi. 10.1177/20451253231212342
- By:
- Publication type:
- Article
A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults.
- Published in:
- Therapeutic Advances in Psychopharmacology, 2023, v. 13, p. 1, doi. 10.1177/20451253231212342
- By:
- Publication type:
- Article
A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.
- Published in:
- Translational Psychiatry, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41398-023-02435-0
- By:
- Publication type:
- Article
Family-based case-control study of homotopic connectivity in first-episode, drug-naive schizophrenia at rest.
- Published in:
- Scientific Reports, 2017, p. 43312, doi. 10.1038/srep43312
- By:
- Publication type:
- Article
Patients with first-episode, drug-naive schizophrenia and subjects at ultra-high risk of psychosis shared increased cerebellar-default mode network connectivity at rest.
- Published in:
- Scientific Reports, 2016, p. 26124, doi. 10.1038/srep26124
- By:
- Publication type:
- Article
Decreased white matter FA values in the left inferior frontal gyrus is a possible intermediate phenotype of schizophrenia: evidences from a novel group strategy.
- Published in:
- European Archives of Psychiatry & Clinical Neuroscience, 2018, v. 268, n. 1, p. 89, doi. 10.1007/s00406-016-0752-z
- By:
- Publication type:
- Article
Central and Peripheral Changes in FOS Expression in Schizophrenia Based on Genome-Wide Gene Expression.
- Published in:
- Frontiers in Genetics, 2019, p. N.PAG, doi. 10.3389/fgene.2019.00232
- By:
- Publication type:
- Article
Randomized, double‐blind, 6‐week non‐inferiority study of lurasidone and risperidone for the treatment of schizophrenia.
- Published in:
- Psychiatry & Clinical Neurosciences, 2020, v. 74, n. 6, p. 336, doi. 10.1111/pcn.12965
- By:
- Publication type:
- Article
WHAT CAN THE MEDICAL EDUCATION DO FOR ELIMINATING STIGMA AND DISCRIMINATION ASSOCIATED WITH MENTAL ILLNESS AMONG FUTURE DOCTORS? EFFECT OF CLERKSHIP TRAINING ON CHINESE STUDENTS' ATTITUDES.
- Published in:
- International Journal of Psychiatry in Medicine, 2014, v. 47, n. 3, p. 241, doi. 10.2190/PM.47.3.e
- By:
- Publication type:
- Article
Preliminary Clinical Investigation of Combinatorial Pharmacogenomic Testing for the Optimized Treatment of Depression: A Randomized Single-Blind Study.
- Published in:
- Frontiers in Neuroscience, 2019, p. 1, doi. 10.3389/fnins.2019.00960
- By:
- Publication type:
- Article
Osteoporosis Associated with Antipsychotic Treatment in Schizophrenia.
- Published in:
- International Journal of Endocrinology, 2013, p. 1, doi. 10.1155/2013/167138
- By:
- Publication type:
- Article
Olanzapine modulates the default-mode network homogeneity in recurrent drug-free schizophrenia at rest.
- Published in:
- Australian & New Zealand Journal of Psychiatry, 2017, v. 51, n. 10, p. 1000, doi. 10.1177/0004867417714952
- By:
- Publication type:
- Article
Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients.
- Published in:
- Neural Regeneration Research, 2013, v. 8, n. 3, p. 277, doi. 10.3969/j.issn.1673-5374.2013.03.011
- By:
- Publication type:
- Article
Tranylcypromine causes neurotoxicity and represses Bhc110/lsD1 in human-induced Pluripotent stem cell-Derived cerebral Organoids Model.
- Published in:
- Frontiers in Neurology, 2017, p. 1, doi. 10.3389/fneur.2017.00626
- By:
- Publication type:
- Article
Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study.
- Published in:
- Neuropsychiatric Disease & Treatment, 2017, v. 13, p. 2045, doi. 10.2147/NDT.S131224
- By:
- Publication type:
- Article